Morgan Stanley analyst Michael Ulz initiated coverage of Fractyl Health with an Overweight rating and $18 price target. The analyst believes Revita and Rejuva have the potential to address the current unmet need in diabetes and obesity, which represent very large markets, through directly modifying the gut and pancreas. The firm says Fractyl has novel approaches to treating metabolic disease.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on GUTS:
- Fractyl Health appoints Conaway to board of directors
- Fractyl Health Appoints Samuel Conaway to Its Board of Directors, Bolstering New Product Commercial Expertise During Revita® Pivotal Clinical Trials
- Fractyl Health IPO Debut Raises $110 Million in Capital
- Fractyl Health Overhauls Governance Structure Post-IPO